The therapeutic potential of gut-specific FXR antagonists is also supported by more recent findings that metformin, a drug of choice for the treatment of type II diabetes, can antagonize FXR signaling in the intestine (Sun et al., 2018). Here, NR1H4 is linked to type 2 diabetes mellitus.